Cambridge, UK., 20 March 2019: Arecor Ltd (“the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that a Phase I Clinical Trial Application (“CTA”) for product candidate AT247 has been approved by the Bundesamt für Sicherheit im […]
Valencia, Calif., USA, and Melbourne, Australia, 13 March 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced that management will present at the Cowen and Company 39th Annual Health Care Conference in Boston. The presentation is being made on 13 March 2019 from 11:20 a.m. to 11:50 a.m. EDT at […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-03-13 01:15:432019-03-22 01:20:57AVITA Medical to Present at Cowen and Company Health Care Conference
Cambridge (UK), 11th March 2019, Arecor Limited (‘Arecor’ or the ’Company’), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce the appointment of Susan Lowther as Chief Financial Officer. Susan was appointed to the board with effect […]
Researchers at Kent and Canterbury Hospital, U.K., are recruiting 20 patients with multiple sclerosis (MS) who can walk at least eight meters with a walking aid to test the effectiveness of a five-week exercise program using assistive robotic technology. A patient completes balance and strengthening exercises using the Rex robot. (Photo courtesy of East Kent Hospitals […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-03-07 01:27:382019-03-22 01:29:25UK Team to Test Robot-assisted Exercise to Improve Balance in MS Patients
COSMOTEC has filed a JPMDA application for approval to market the RECELL System in Japan Valencia, Calif., USA, and Melbourne, Australia, 4 March 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced that it has collaborated with COSMOTEC, an M3 Group company, to market and distribute the RECELL® Autologous Cell […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-03-04 02:48:212019-03-15 03:19:50Avita Medical Announces Collaboration with COSMOTEC, an M3 Group Company, to Commercialize the RECELL® System in Japan
–Sales temporarily interrupted while closing administrative and procedural open items related to EU certificates and unrelated to product performance -No impact on U.S. market Valencia, Calif., USA, and Melbourne, Australia, 4 March 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that sales of the RECELL® Device in the […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-03-03 02:40:322019-03-15 02:47:46AVITA Medical Announces Temporary Interruption of Sales of Products in EU
Valencia, Calif., USA, and Melbourne, Australia, 28 February 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced that it filed today with the ASX its Appendix 4D – Half-Year Report for the six months ended 31 December 2018. Revenues for First Six Months and Update on U.S. National Market Launch […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-02-28 02:19:122019-03-15 02:39:55Avita Medical Half-Year Financial Report for Fiscal 2019
Value Proposition of Integrated ADC Manufacturing Processes – Use of Economic Modelling-Poster will be presented at 9th Annual World ADC. Abstract Development and manufacture of biologic-drug conjugates involves a complex supply chain of multiple, different specialised contracted cGMP facilities. CDMOs have simplified project & contractual arrangements either by forming supplier collaborations or by acquiring specialised facilities […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-02-22 02:06:122019-03-15 02:07:07ADC BIO WILL BE PRESENTING AT 9TH ANNUAL WORLD ADC LONDON CONFERENCE
Super-fast product addresses critical unmet need in development of next generation artificial pancreas systems” “Novel formulation significantly accelerates absorption of insulin post injection – accelerating the onset of glucose lowering.” Cambridge, UK., 13 February 2019: Arecor Ltd (“the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for […]
Charlie Johnson, CEO of biotechnology company ADC Bio, explains how substantial cost savings and faster time to market is achievable through the novel concept of combining the bioconjugation and purification steps. Charlie Johnson – CEO, ADC Bio As an advanced manufacturing concept, integrated bioconjugation is highly promising – and is now under development – with the […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-02-13 03:03:222019-02-14 11:29:52How Forward Thinking and New Approaches Will Drive Up Efficiency
ARECOR RECEIVES REGULATORY APPROVAL TO INITIATE PHASE I CLINICAL TRIAL FOR ULTRA-RAPID ACTING INSULIN PRODUCT
/in ArecorCambridge, UK., 20 March 2019: Arecor Ltd (“the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that a Phase I Clinical Trial Application (“CTA”) for product candidate AT247 has been approved by the Bundesamt für Sicherheit im […]
AVITA Medical to Present at Cowen and Company Health Care Conference
/in Avita MedicalValencia, Calif., USA, and Melbourne, Australia, 13 March 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced that management will present at the Cowen and Company 39th Annual Health Care Conference in Boston. The presentation is being made on 13 March 2019 from 11:20 a.m. to 11:50 a.m. EDT at […]
ARECOR APPOINTS CHIEF FINANCIAL OFFICER
/in ArecorCambridge (UK), 11th March 2019, Arecor Limited (‘Arecor’ or the ’Company’), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce the appointment of Susan Lowther as Chief Financial Officer. Susan was appointed to the board with effect […]
UK Team to Test Robot-assisted Exercise to Improve Balance in MS Patients
/in Rex BionicsResearchers at Kent and Canterbury Hospital, U.K., are recruiting 20 patients with multiple sclerosis (MS) who can walk at least eight meters with a walking aid to test the effectiveness of a five-week exercise program using assistive robotic technology. A patient completes balance and strengthening exercises using the Rex robot. (Photo courtesy of East Kent Hospitals […]
Avita Medical Announces Collaboration with COSMOTEC, an M3 Group Company, to Commercialize the RECELL® System in Japan
/in Avita MedicalCOSMOTEC has filed a JPMDA application for approval to market the RECELL System in Japan Valencia, Calif., USA, and Melbourne, Australia, 4 March 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced that it has collaborated with COSMOTEC, an M3 Group company, to market and distribute the RECELL® Autologous Cell […]
AVITA Medical Announces Temporary Interruption of Sales of Products in EU
/in Avita Medical–Sales temporarily interrupted while closing administrative and procedural open items related to EU certificates and unrelated to product performance -No impact on U.S. market Valencia, Calif., USA, and Melbourne, Australia, 4 March 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that sales of the RECELL® Device in the […]
Avita Medical Half-Year Financial Report for Fiscal 2019
/in Avita MedicalValencia, Calif., USA, and Melbourne, Australia, 28 February 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced that it filed today with the ASX its Appendix 4D – Half-Year Report for the six months ended 31 December 2018. Revenues for First Six Months and Update on U.S. National Market Launch […]
ADC BIO WILL BE PRESENTING AT 9TH ANNUAL WORLD ADC LONDON CONFERENCE
/in ADC BioValue Proposition of Integrated ADC Manufacturing Processes – Use of Economic Modelling-Poster will be presented at 9th Annual World ADC. Abstract Development and manufacture of biologic-drug conjugates involves a complex supply chain of multiple, different specialised contracted cGMP facilities. CDMOs have simplified project & contractual arrangements either by forming supplier collaborations or by acquiring specialised facilities […]
Super-fast-acting Prandial Insulin Product Receives £0.5m Innovate UK Boost
/in ArecorSuper-fast product addresses critical unmet need in development of next generation artificial pancreas systems” “Novel formulation significantly accelerates absorption of insulin post injection – accelerating the onset of glucose lowering.” Cambridge, UK., 13 February 2019: Arecor Ltd (“the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for […]
How Forward Thinking and New Approaches Will Drive Up Efficiency
/in ADC BioCharlie Johnson, CEO of biotechnology company ADC Bio, explains how substantial cost savings and faster time to market is achievable through the novel concept of combining the bioconjugation and purification steps. Charlie Johnson – CEO, ADC Bio As an advanced manufacturing concept, integrated bioconjugation is highly promising – and is now under development – with the […]